Table 2 STING agonists for cancer immunotherapy
Agents | Delivery | Molecular Type | Combination therapy | Clinical trials | Cancer types | Phase |
|---|---|---|---|---|---|---|
ADU-S100 | IT | CDN analog | Pembrolizumab | NCT03937141 | Advanced head and neck cancer | 2 |
Ipilimumab | NCT02675439 | Advanced solid tumors or lymphomas | 1 | |||
PDR001 (Anti-PD-1) | NCT03172936 | Advanced solid tumors or lymphomas | 1 | |||
MK-1454 | IT | CDN analog | Pembrolizumab | NCT04220866 | Advanced head and neck cancer | 2 |
Pembrolizumab | NCT03010176 | Advanced solid tumors or lymphomas | 1 | |||
MK-2118 | IT or SC | Non-CDN | Pembrolizumab | NCT03249792 | Advanced solid tumors or lymphomas | 1 |
SB11285 | IV | CDN analog | Atezolizumab | NCT04096638 | Advanced solid tumors | 1 |
GSK3745417 | IV | Non-CDN | NA (Monotherapy) | NCT05424380 | Refractory myeloid malignancies | 1 |
Dostarlimab | NCT03843359 | Advanced solid tumors | 1 | |||
BMS-986301 | IM or IV or IT | CDN analog | Nivolumab or Ipilimumab | NCT03956680 | Advanced solid tumors | 1 |
BI 1387446 | IT | CDN analog | Ezabenlimab | NCT04147234 | Advanced solid tumors | 1 |
E7766 | IT | Non-CDN | NA (Monotherapy) | NCT04144140 | Advanced solid tumors or lymphomas | 1 |
NA (Monotherapy) | NCT04109092 | Bladder cancer | 1 | |||
TAK-676 | IV | CDN analog | Pembrolizumab | NCT04879849 | Advanced solid tumors | 1 |
Pembrolizumab | NCT04420884 | Advanced solid tumors | 1 | |||
SNX281 | IV | Non-CDN | Pembrolizumab | NCT04609579 | Advanced solid tumors or lymphomas | 1 |
SYNB1891 | IT | Engineered bacteria vectors | Atezolizumab | NCT04167137 | Advanced solid tumors or lymphomas | 1 |
Manganese | Inhalation | Non-CDN | Radiotherapy | NCT04873440 | Advanced solid tumors or lymphomas | 1/2 |